EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of medulloblastoma

EANO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up of post-pubertal and adult patients with medulloblastoma

The European Association of Neuro-Oncology (EANO) and EUropean RAre CANcer (EURACAN) guideline provides recommendations for the diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. The guideline is based on the 2016 WHO classification of tumours of the CNS and on scientific developments published since 1980. It aims to provide direction for diagnostic and management decisions, and for limiting unnecessary treatments and cost. In view of the scarcity of data in adults with medulloblastoma, we base our recommendations on adult data when possible, but also include recommendations derived from paediatric data if justified. Our recommendations are a resource for professionals involved in the management of post-pubertal and adult patients with medulloblastoma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary structures of care, and defined processes of diagnosis and treatment.

Click here to read published version (Lancet Oncol 2019; 20: e715–28  DOI:https://doi.org/10.1016/S1470-2045(19)30669-2 Published:December 2019)

Declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided. Declarations must include any payments, honorarium or arrangement for re-imbursement of expenses, relevant for any aspect of his/her involvement with EANO, that has been provided by commercial companies.

Log in to edit your data

EANO Conflict of Interest Disclosure